IBRX ▲ +2.1% - ImmunityBio, Inc.
$IBRX FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
14-OCT-2026 04:19 PM ET
Share this post
More filings for $IBRX
IBRX ▲ +2.1% - ImmunityBio, Inc.Oct 14, 2026IBRX ▲ +1.0% - ImmunityBio, Inc.Oct 14, 2026IBRX ▼ -0.2% - ImmunityBio, Inc.Oct 14, 2026IBRX ▼ -0.2% - ImmunityBio, Inc.Oct 14, 2026IBRX ▼ -0.2% - ImmunityBio, Inc.Oct 14, 2026IBRX ▲ +5.1% - ImmunityBio, Inc.Oct 9, 2026
View full $IBRX filing history →💬 Comments
Loading comments…
Leave a comment